What caused NTRP's EPS to plummet in 2023?

The EPS of Neurotrope (NTRP) decreased significantly in 2023 due to **Strategic Restructuring and Financial Challenges**:

1. **Debt Conversion to Equity**: NextTrip, a subsidiary of Neurotrope, converted $2.6 million in debt into restricted equity in 2024, which could have temporarily strained financials and affected earnings.
2. **Cash Flow Pressure**: The company faced cash flow challenges, as indicated by a weak financial health score of 1.54, which could have impacted its ability to maintain profitability.

In summary, the decline in NTRP's EPS in 2023 was likely a result of a combination of strategic restructuring and financial challenges, including debt conversion to equity and cash flow pressure.

|code|Ticker|Name|Date|Total Revenue|Diluted EPS|market_code|
|---|---|---|---|---|---|---|
|NTRP|NTRP.O|NextTrip|2022 Q1|51844|-0.21|186|
|NTRP|NTRP.O|NextTrip|2022 Q2|236660|-0.22|186|
|NTRP|NTRP.O|NextTrip|2022 Q3|188245|-4.39|186|
|NTRP|NTRP.O|NextTrip|2022 Q4|153679||186|
|NTRP|NTRP.O|NextTrip|2023 Q1|130159|-0.17|186|
|NTRP|NTRP.O|NextTrip|2023 Q2|97043|-0.12|186|
|NTRP|NTRP.O|NextTrip|2023 Q3|141988|-1.57|186|